Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02231593 · ClinicalTrials.gov registry record
SAGIT for Classification of Patients With Acromegaly in Clinical Practice
A clinical trial, sponsored by Ipsen.
- Completed
- Registry status
- 71
- Enrollment target
NCT02231593 is a clinical trial that has completed, run by Ipsen. The registered enrollment target is 71 participants.
The verdict
NCT02231593 has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to test SAGIT (Signs and symptoms - Associated comorbidities - GH concentration level - IGF-1 - Tumour). SAGIT is a Clinician-Reported Outcomes (ClinROs) tool developed to describe patients with acromegaly. This study will determine the potential use of a finalised operational version for patient classification in clinical practice and studies. In addition, this study intends to carry out a qualitative evaluation of the acceptability of SAGIT by the practicing endocrinologist in terms of relevance, ease of use, applicability and usefulness of the tool in practice.
Interventions
- OTHER SAGIT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02231593
The ClinicalTrials.gov registry entry for NCT02231593 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SAGIT is the first listed.
NCT02231593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02231593 about?
NCT02231593 is a clinical study titled "SAGIT for Classification of Patients With Acromegaly in Clinical Practice". The purpose of this pilot study is to test SAGIT (Signs and symptoms - Associated comorbidities - GH concentration level - IGF-1 - Tumour). SAGIT is a Clinician-Reported Outcomes (ClinROs) tool developed to describe patients with acromegaly. This study will determine the potential use of a finalised...
What is the current status of trial NCT02231593?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2013-02. Estimated completion is 2014-05.
What interventions are being tested in trial NCT02231593?
The interventions under investigation include: SAGIT (OTHER).
Who is sponsoring clinical trial NCT02231593?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.